In addition, SGLT2 inhibitors have been found to relieve hyperuricemia in diabetic mice (Lu et al. 2020), and obesity in high fat-fed mice via enhancing CREB phosphorylation (Yang et al. 2021). This evidence concerns the gene CREB1 and hyperuricemia.